PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
53.82%
Cash & equivalents growing 53.82% while AXSM's declined -21.72%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
53.82%
Below half of AXSM's -21.72%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
54.98%
Below half of AXSM's -21.38%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-8.67%
Below half AXSM's 3.88%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.00%
Below half of AXSM's -27.51%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
53.46%
Below half of AXSM's -21.42%. Michael Burry sees a potential red flag for stagnation or capital shortage.
21.21%
Above 1.5x AXSM's 12.78%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-57.02%
50-75% of AXSM's -92.60%. Bruce Berkowitz notes a more controlled liability line.
37.02%
Less than half of AXSM's -22.62%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.02%
Less than half of AXSM's -18.50%. David Dodd sees far fewer liability expansions relative to competitor.
37.77%
Above 1.5x AXSM's 0.24%. Michael Burry suspects heavy new equity expansion or dilution.
-3.87%
0.5-0.75x AXSM's -6.27%. Martin Whitman is wary of weaker retention or lower profitability.
-5.55%
Less than half of AXSM's -100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
59.08%
0.5-0.75x AXSM's 116.43%. Martin Whitman is wary of lagging equity growth vs. competitor.
53.46%
Below half AXSM's 148.38%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.82%
Less than half of AXSM's 27.66%. David Dodd sees better deleveraging or stronger cash buildup than competitor.